Skip to Main Content

4,308

Views

5

CrossRef citations to date

0

Altmetric

Articles

Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study

Habte Yimera Texas Oncology, Tyler/US Oncology Research, Tyler, TX, USAView further author information

,

Jason Melearb Texas Oncology, Austin, TX, USAView further author information

,

Edward Faberc Oncology Hematology Care, Inc, Cincinnati, OH, USAView further author information

,

William I. Bensingerd Swedish Cancer Institute, Seattle, WA, USAView further author information

,

John M. Burkee US Oncology Research, Rocky Mountain Cancer Centers, Aurora, CO, USAView further author information

,

Mohit Narangf US Oncology Research, Maryland Oncology Hematology, Columbia, MD, USAView further author information

,

Don Stevensg Norton Health Care, Louisville, KY, USAView further author information

,

Kathleen S. Grayh Janssen Scientific Affairs, LLC, Horsham, PA, USAView further author information

,

Yana Lutskah Janssen Scientific Affairs, LLC, Horsham, PA, USAView further author information

,

Padma Bobbah Janssen Scientific Affairs, LLC, Horsham, PA, USAView further author information

,

Keqin Qii Janssen Research & Development, LLC, Titusville, NJ, USAView further author information

,

Daniela Hoehnh Janssen Scientific Affairs, LLC, Horsham, PA, USAView further author information

,

Ming Qij Janssen Research & Development, LLC, Spring House, PA, USAView further author information

,

Thomas S. Linh Janssen Scientific Affairs, LLC, Horsham, PA, USAView further author information

&

Robert M. Rifkink US Oncology Research, Rocky Mountain Cancer Centers, Denver, CO, USACorrespondence[email protected]
View further author information